The call comes after GlaxoSmithKline received the first positive opinion from the European Medicines Agency for the use of its H5N1 pre-pandemic vaccine, Prepandrix.
Results from a series of clinical trials have shown that Prepandrix can offer protection against a number of H5N1 variant strains currently circulating.
Dr George Kassianos, RCGP immunisation spokesman and Berkshire GP, welcomed the decision to approve Prepandrix for use against an influenza pandemic.
‘The threat of a pandemic is very real, so we need to be prepared for it.'
Comment below and tell us what you think